CL2014000956A1 - Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. - Google Patents

Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.

Info

Publication number
CL2014000956A1
CL2014000956A1 CL2014000956A CL2014000956A CL2014000956A1 CL 2014000956 A1 CL2014000956 A1 CL 2014000956A1 CL 2014000956 A CL2014000956 A CL 2014000956A CL 2014000956 A CL2014000956 A CL 2014000956A CL 2014000956 A1 CL2014000956 A1 CL 2014000956A1
Authority
CL
Chile
Prior art keywords
phenylimidazol
ethylamine
pain
treatment
pharmaceutical composition
Prior art date
Application number
CL2014000956A
Other languages
English (en)
Spanish (es)
Inventor
Shranjeet Kaur Bagal
Mark Ian Kemp
Duncan Charles Miller
Yoshihisa Murata
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000956(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CL2014000956A1 publication Critical patent/CL2014000956A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2014000956A 2011-10-26 2014-04-14 Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. CL2014000956A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26

Publications (1)

Publication Number Publication Date
CL2014000956A1 true CL2014000956A1 (es) 2014-07-18

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000956A CL2014000956A1 (es) 2011-10-26 2014-04-14 Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.

Country Status (28)

Country Link
US (1) US9079878B2 (OSRAM)
EP (1) EP2771335A2 (OSRAM)
JP (1) JP5946538B2 (OSRAM)
KR (1) KR101586966B1 (OSRAM)
CN (1) CN103906746B (OSRAM)
AP (1) AP2014007579A0 (OSRAM)
AU (1) AU2012328034B2 (OSRAM)
BR (1) BR112014009102A2 (OSRAM)
CA (1) CA2850925C (OSRAM)
CL (1) CL2014000956A1 (OSRAM)
CO (1) CO6940427A2 (OSRAM)
CR (1) CR20140185A (OSRAM)
CU (1) CU20140046A7 (OSRAM)
DO (1) DOP2014000085A (OSRAM)
EA (1) EA023375B1 (OSRAM)
EC (1) ECSP14013324A (OSRAM)
GT (1) GT201400079A (OSRAM)
IL (1) IL232267A (OSRAM)
MD (1) MD20140037A2 (OSRAM)
MX (1) MX337469B (OSRAM)
NI (1) NI201400031A (OSRAM)
PE (1) PE20141682A1 (OSRAM)
PH (1) PH12014500919A1 (OSRAM)
SG (1) SG11201401032YA (OSRAM)
TN (1) TN2014000147A1 (OSRAM)
UA (1) UA109220C2 (OSRAM)
WO (1) WO2013061205A2 (OSRAM)
ZA (1) ZA201402281B (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014003064A (es) * 2011-09-14 2014-05-07 Dow Agrosciences Llc Metodos y sistemas para formar acidos boronicos y sus intermedios.
SMT201800521T1 (it) 2013-12-13 2018-11-09 Vertex Pharma Profarmaci di piridonammidi utili come modulatori di canali del sodio
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
CA2965509C (en) 2014-10-24 2023-03-14 Avectas Limited Delivery across cell plasma membranes
WO2016134283A1 (en) 2015-02-19 2016-08-25 Purdue Pharma L.P. Methods and compositions for decreasing gastric emptying
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
US11827899B2 (en) 2015-12-30 2023-11-28 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
CA3029132A1 (en) * 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
JP7548696B2 (ja) 2016-07-06 2024-09-10 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛関連障害を処置するための物質及び方法
WO2018213426A1 (en) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
WO2019014352A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
JP2021512935A (ja) 2018-02-12 2021-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 疼痛を処置する方法
AU2019372057A1 (en) 2018-11-02 2021-05-27 Merck Sharp & Dohme Llc 2-amino-N-heteroaryl-nicotinamides as NAV1.8 inhibitors
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
US20240368135A1 (en) 2021-06-04 2024-11-07 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
US20250213555A1 (en) 2021-06-04 2025-07-03 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
EP4346818B1 (en) 2021-06-04 2025-12-03 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
JP2024520643A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
KR20250005373A (ko) 2022-04-22 2025-01-09 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
EP4511114A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
EP4511115A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3256486A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics Inc Bicyclic Na V1.8 Heterocyclic Amide Inhibitors for Pain Management
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202523313A (zh) 2023-10-23 2025-06-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
JP4173191B2 (ja) * 2004-05-07 2008-10-29 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｈ３リガンドとして有用な３‐または４‐一置換フェノールおよびチオフェノール誘導体
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
SG158921A1 (en) 2004-10-27 2010-02-26 Schering Corp Compositions and methods for short interfering nucleic acid inhibition of nav1.8
SI1963280T1 (sl) * 2005-12-22 2016-02-29 Newron Pharmaceuticals S.P.A. 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
CA2681572C (en) 2007-03-23 2014-02-11 Icagen, Inc. Inhibitors of ion channels
KR20100007956A (ko) 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
US20100227872A1 (en) * 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
KR101586966B1 (ko) 2016-01-19
HK1198650A1 (en) 2015-05-22
IL232267A (en) 2016-10-31
AU2012328034A1 (en) 2014-05-15
IL232267A0 (en) 2014-06-30
PH12014500919A1 (en) 2014-06-09
CR20140185A (es) 2014-06-03
EA023375B1 (ru) 2016-05-31
KR20140069234A (ko) 2014-06-09
ZA201402281B (en) 2015-11-25
AP2014007579A0 (en) 2014-04-30
WO2013061205A8 (en) 2014-03-27
CN103906746B (zh) 2015-12-09
ECSP14013324A (es) 2014-05-31
MD20140037A2 (ro) 2014-08-31
CN103906746A (zh) 2014-07-02
US20140296313A1 (en) 2014-10-02
US9079878B2 (en) 2015-07-14
EP2771335A2 (en) 2014-09-03
CA2850925C (en) 2017-01-10
PE20141682A1 (es) 2014-11-14
BR112014009102A2 (pt) 2017-04-18
EA201490864A1 (ru) 2014-08-29
CO6940427A2 (es) 2014-05-09
DOP2014000085A (es) 2014-08-31
NZ623090A (en) 2015-10-30
NI201400031A (es) 2014-10-01
CA2850925A1 (en) 2013-05-02
WO2013061205A2 (en) 2013-05-02
WO2013061205A3 (en) 2013-06-27
UA109220C2 (uk) 2015-07-27
JP2014530900A (ja) 2014-11-20
SG11201401032YA (en) 2014-07-30
GT201400079A (es) 2015-06-02
CU20140046A7 (es) 2014-10-02
AU2012328034B2 (en) 2015-04-23
MX2014004738A (es) 2014-08-01
TN2014000147A1 (fr) 2015-09-30
JP5946538B2 (ja) 2016-07-06
MX337469B (es) 2016-03-02

Similar Documents

Publication Publication Date Title
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
CL2016000106A1 (es) Sulfonamidas como moduladores de canales de sodio.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
CL2016000381A1 (es) Compuestos antivirales
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2018000883A1 (es) Moduladores del receptor x farnesoide
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2013000713A1 (es) Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial.
MY188139A (en) Sodium channel modulators for the treatment of pain
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
EA201790461A1 (ru) Композиции внеклеточного матрикса
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante